7-(2-methyl-1,5-dihydropyrazol-4-yl)-5-(6-piperazin-1-yl-3-pyridinyl)imidazo[1,2-a]pyridine-3-carbonitrile
C21H22N8 — CID 155301240
Data last refreshed: (MolForge compound catalog, from PubChem)
About 7-(2-methyl-1,5-dihydropyrazol-4-yl)-5-(6-piperazin-1-yl-3-pyridinyl)imidazo[1,2-a]pyridine-3-carbonitrile
7-(2-methyl-1,5-dihydropyrazol-4-yl)-5-(6-piperazin-1-yl-3-pyridinyl)imidazo[1,2-a]pyridine-3-carbonitrile (PubChem CID 155301240) has the molecular formula C21H22N8 and a molecular weight of 386.46 g/mol. Its IUPAC name is 7-(2-methyl-1,5-dihydropyrazol-4-yl)-5-(6-piperazin-1-yl-3-pyridinyl)imidazo[1,2-a]pyridine-3-carbonitrile.
Molecular Properties
| Compound Name | 7-(2-methyl-1,5-dihydropyrazol-4-yl)-5-(6-piperazin-1-yl-3-pyridinyl)imidazo[1,2-a]pyridine-3-carbonitrile |
|---|---|
| PubChem CID | 155301240 |
| Molecular Formula | C21H22N8 |
| Molecular Weight | 386.46 g/mol |
| Exact Mass | 386.20 |
| IUPAC Name | 7-(2-methyl-1,5-dihydropyrazol-4-yl)-5-(6-piperazin-1-yl-3-pyridinyl)imidazo[1,2-a]pyridine-3-carbonitrile |
| SMILES | CN1C=C(c2cc(-c3ccc(N4CCNCC4)nc3)n3c(C#N)cnc3c2)CN1 |
| InChI | InChI=1S/C21H22N8/c1-27-14-17(12-26-27)16-8-19(29-18(10-22)13-25-21(29)9-16)15-2-3-20(24-11-15)28-6-4-23-5-7-28/h2-3,8-9,11,13-14,23,26H,4-7,12H2,1H3 |
| InChIKey | GNSWVHWLCHXWFL-UHFFFAOYSA-N |
| XLogP | 1.47 |
| TPSA | 84.52 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 386.46 |
| LogP ≤ 5 | 1.47 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155301240 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.